A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs UB 312 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors United Neuroscience
- 28 Aug 2019 Status changed from planning to recruiting.
- 30 Nov 2018 New trial record
- 13 Nov 2018 According to an United Neuroscience media release, this trial is expected to start in 2019.